Ygal Nochomovitz

Ygal Nochomovitz is a Director and SMid Cap Biotech Analyst at Citi, specializing in in-depth equity research across the biotechnology sector with a focus on companies in ophthalmology, oncology, rare diseases, nephrology, and infectious disease spaces. He covers a large portfolio of biotech stocks including names such as APLS, LXRX, and MRTX, and has achieved an average returns rate of 3.1% per transaction with a 38% success rate, highlighted by a top-performing call on RETA stock with a 675.5% return. Nochomovitz joined Citi in 2015 after senior analyst and vice president roles at Oppenheimer, Morgan Stanley, Rodman & Renshaw, and SIG Susquehanna, and he began his Wall Street career in 2008 after postdoctoral work at Rockefeller University. He holds a PhD in Biophysics from the University of California, San Francisco, a BS in Biochemistry from Brown University, and maintains professional credentials including required FINRA registrations for equity research analysts.